ATH-063

DRUG2 trials

Sponsors

Athos Therapeutics Inc

Conditions

Autoimmune DiseasesCrohn DiseaseInflammatory Bowel DiseasesUlcerative Colitis

Phase 1

Assessment of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ATH-063 in Healthy Subjects

CompletedNCT05807971

Athos Therapeutics IncAutoimmune Diseases, Crohn Disease, Inflammatory Bowel Diseases +1

Start: 2023-04-06End: 2024-02-08Updated: 2024-05-03

Phase 2

Proof of Concept Study Evaluating the Efficacy and Safety of ATH-063 Treatment in Patients With Relapsed/Refractory Moderately to Severely Active Ulcerative Colitis (UC)

Not yet recruitingNCT07513181

Athos Therapeutics IncAutoimmune Diseases, Inflammatory Bowel Diseases, Ulcerative Colitis

Start: 2026-06-01End: 2028-12-14Target: 120Updated: 2026-06-08

Related Papers

RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED PHASE 1 STUDY OF ATH-063: A NOVEL, ORAL, ARTIFICIAL INTELLIGENCE-GENERATED DRUG FOR INFLAMMATORY BOWEL DISEASE

Inflammatory Bowel Diseases2026-01-22